LANTOROL

Lantorol (Capsules)
(Lansoprazole)


CONTENT:
Capsules. Capsule contains lansoprazole 30 mg.
 
PHARMACOLOGICAL PROPERTIES:
PHARMACODYNAMICS. Lantorol is an antiulcer agent, specific proton pump inhibitor (H+- K+- ATPase). Lansoprazole is metabolized in parietal stomach cells to active sulfonamide derivatives, which inactivate sulfhydric groups of H+- K+-ATPase. This blocks the final step of hydrochloric acid production and leads to inhibition of basal and stimulated gastric hydrochloric acid secretion regardless of the stimulus nature.
Lantorol inhibits Helicobacter pylori growth and increases activity against Helicobacter pylori of other drugs.
PHARMACOKINETICS. The absorption after oral administration is high. The maximum concentration is reached after 1.5-2.2 hours.
 
THERAPEUTIC INDICATIONS:
- ulcer of stomach and duodenum;
- erosive-ulcer stomach and duodenum involvements, connected with nonsteroidal anti-inflammatory drugs (NSAID) administration, stress ulcers;
- gastroesophageal reflux disease (GERD): curative treatment of reflux-esophagitis, symptomatic treatment of reflux-esophagitis;
- eradication of Helicobacter pylori (in combination with antibiotics);
- pathological hypersecretory conditions, including Zollinger-Ellison syndrome;
- chronic gastritis with raised stomach acid-forming function in an exacerbation stage;
- non-ulcer dyspepsia.
 
CONTRAINDICATIONS:
- hypersensitivity to drug components;
- malignant neoplasms in GIT;
- child and juvenile age till 18 years;
- first trimester of pregnancy, lactation period.
 
SIDE EFFECTS:
In gastrointestinal tract: diarrhea, increase or decrease of appetite, nausea, stomachache, constipation.
In central nervous system (CNS): headache, weakness, dizziness, sleepiness, depression, anxiety.
Allergic reactions: skin eruption.
Other: in single cases - influenza-like syndrome, myalgia.
 
DOSAGE AND ADMINISTRATION:
Lantorol is used orally as a whole, not chewing, regardless of food intake.
Ulcer of stomach and duodenum: prescribe 30 mg/day. Course of treatment during exacerbation of duodenum ulcer is 2-4 weeks and for stomach ulcer 4-8 weeks.
Erosions or ulcers of stomach or duodenum, connected with NSAID administration: recommended dose is 30 mg per day, course of treatment - 4-8 weeks. Prophylaxis of ulcer of stomach and duodenum at patients in risk group in connection with NSAID administration: 15 mg/day till 12 weeks.
GERD (treatment of reflux-esophagitis): prescribe 30 mg/day during 4-8 weeks; prolonged treatment up to 8 weeks, if necessary.
Symptomatic treatment of reflux-esophagitis: prescribe 15 mg/day; course of treatment up to 8 weeks.
Maintenance therapy of reflux-esophagitis: 15 mg/day during 8 weeks; prolong the course of treatment up to 8 weeks, but not more than 12 weeks, if necessary.
Eradication of Helicobacter pylori: take 30 mg 2 times per day in combination with antibiotics.
Pathological hypersecretory conditions, including Zollinger-Ellison syndrome: initial dose of drug is 30 mg 2 times per day, the dose is increased till 120 mg/day. Course of treatment is determined individually.
Chronic gastritis with raised stomach acid-forming function in an exacerbation stage: prescribe 30 mg 1-2 times per day. Course of treatment is 2-3 weeks.
Non-ulcer dyspepsia: prescribe 15-30 mg 1-2 times per day. Course of treatment is 2-3 weeks.
At hepatic insufficiency and in patients of elderly age the treatment begins from half doses, gradually increases to recommended, but not more than 30 mg/day.
 
PACKAGING:
14 capsules in blister.
1 or 2 blister in a carton box with leaflet.